Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
Date:4/26/2013

NANJING, China, April 26, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll: 

+65.6723.9381United States toll-free: 

+1.866.519.4004United States toll: 

+1.718.354.1231China Domestic toll: 

800.819.0121 China Domestic mobile toll: 

400.620.8038 Hong Kong toll: 

+852.2475.0994Please ask to be connected to Q1 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 58031483.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1. 855.452.5696United States toll:

+1. 646.254.3697The passcode for replay participants is 58031483. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:Jie Liu D'EliaVice PresidentSimcere Pharmaceutical GroupTel: 86-25-8556-6666*8857In the United States:Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810In Beijing: Yue YuBrunswick GroupTel: 86-10-5960-8 

 

 


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
2. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
3. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
4. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
6. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
7. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
9. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
10. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
11. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):